We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The Tyrosine Kinase Inhibitor Dasatinib Dysregulates Bone Remodeling Through Inhibition of Osteoclasts In Vivo.
- Authors
Vandyke, Kate; Dewar, Andrea L.; Diamond, Peter; Fitter, Stephen; Schultz, Christopher G.; Sims, Natalie A.; Zannettino, Andrew C. W.
- Abstract
The article discusses a study on dasatinib and its role in dysregulating bone remodeling by inhibiting osteoclasts in vivo. According to the authors, dasatinib is an effective tyrosine kinase inhibitor that is used to treat chronic myeloid leukemia in patients that are intolerant to imatinib mesylate. The results of the study found that dasatinib increases trabecular bone volume by inhibiting osteoclast activity.
- Subjects
BONE remodeling; PROTEIN-tyrosine kinase inhibitors; OSTEOCLASTS; LEUKEMIA treatment; MYELOID leukemia; THERAPEUTICS
- Publication
Journal of Bone & Mineral Research, 2010, Vol 25, Issue 8, p1759
- ISSN
0884-0431
- Publication type
Article
- DOI
10.1002/jbmr.85